secwatch.observer — SEC 8-K summary
======================================

Issuer:     OS Therapies Inc (OSTX)
CIK:        0001795091
Form:       8-K
Filed at:   2024-10-28T23:59:59+00:00
Accession:  0001213900-24-091235
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OS Therapies appoints two new independent directors; Chairman Goddard and Joacim Borg resign
--------------------------------------------------------------------------------

- Colin Goddard (Chairman) and Joacim Borg resigned effective Oct 28, 2024; no disagreement with company operations.
- Avril McKean Dieser appointed independent director; VP, Head Legal Patient Evidence at UCB; regulatory/commercialization expertise.
- Olivier R. Jarry appointed independent director; co-founder/CEO of Libera Bio; 40+ years biopharma experience.
- Company preparing for FDA discussion on pivotal trial of OST-HER2 for osteosarcoma; building infrastructure for potential commercial launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1795091/000121390024091235/0001213900-24-091235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1795091/000121390024091235/ea0218797-8k_osthera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-091235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer